Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access
Globe Newswire•19/11/2026•08:00 ET
0
Key Highlights
- ➤Humacyte (HUMA) submits sBLA seeking hemodialysis access approval for ATEV
- ➤sBLA supported by three Phase 3 studies in hemodialysis access
- ➤V012 women achieved functional access more than three months sooner with ATEV
- ➤FDA has 60 days to determine filing acceptance and review timeline
- ➤Humacyte requested Priority Review for the hemodialysis access application
Expert Statements
Laura Niklason, Co-Founder and Chief Executive Officer of Humacyte
“Submission of our sBLA for ATEV in hemodialysis access is a significant milestone for Humacyte and an important step toward giving patients on dialysis a potential new access option”
Laura Niklason, Co-Founder and Chief Executive Officer of Humacyte
“I want to thank the patients and medical professionals who participated in our three Phase 3 clinical studies, and our Humacyte team for their tremendous effort and dedication in completing the sBLA submission.”
Laura Niklason, Co-Founder and Chief Executive Officer of Humacyte
“We believe the ATEV has the potential to address a significant unmet need for patients who depend on hemodialysis, and we look forward to working closely with the FDA during its review.”
Laura Niklason, Co-Founder and Chief Executive Officer of Humacyte
“For too long, patients on dialysis, and women in particular, have had to settle for access options that often do not work well for them, leaving many reliant on infection-prone catheters.”
Laura Niklason, Co-Founder and Chief Executive Officer of Humacyte
“We are excited about the potential of the ATEV to provide a new potential vascular access option for patients in need.”
Laura Niklason, Co-Founder and Chief Executive Officer of Humacyte
“This submission brings us one step closer to our goal of providing a new vascular access option for patients on hemodialysis,”
Laura Niklason, Co-Founder and Chief Executive Officer of Humacyte
“We look forward to the FDA’s review and remain focused on the opportunity to make a meaningful difference for patients in need of vascular access.”
–sBLA submission seeks to add arteriovenous access for hemodialysis as second approved indication for the ATEV.
–sBLA supported by results from three Phase 3 studies in hemodialysis access.
Get started
Create a free account to read the full story.
